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Among many challenges in chemotherapy of cancer diseases,
overtreatment remains one of the greatest. A substantial propor-
tion of patients, perhaps the majority, do not benefit from the
chemotherapy that they are offered, either in the adjuvant or in the
palliative situation. In the adjuvant situation this is particularly
serious, as the same patients will often experience the side-effects
following the therapy. For such patients, there is no immediate
way to assess the value of therapy.
The response of cancer cells to chemotherapy can simplistically
be illustrated as related to two basic, pharmacological character-
istics. The first is the accessibility of the therapeutic principle to
the cancer cell: the drug in its active form has to reach the target,
the malignant cell, wherever it is located. The second is the
inherent sensitivity in the target cells, the cancer cells, to the treat-
ment principle. This sensitivity results from a combination of
genetic predisposition and acquired resistance. The acquired resis-
tance could be due to previous exposure to toxic substances or be a
characteristic from malignant evolution. The sensitivity versus
resistance, or the expression of this relation in a tumour cell
population, seems to be related to cell proliferation.
If the sensitivity of tumour cells to therapeutic principles is a
reflection of the genetic predisposition, this sensitivity would
theoretically be the same in all cells in an individual. If, on a
given schedule of chemotherapy, the leucocyte nadir is low, this
could then indicate more adequate exposure of drug to the tumour
cells (and all other cells) in that individual.
In addition to the individual sensitivity-based genetic pre-
disposition, tumour responsiveness to specific drugs, such as
anthracyclines and cisplatinum, is probably also related to genetic
changes in the tumour cells. Examples are p53 mutations, which
seem to indicate lack of response to CMF and doxorubicin (Aas
et al, 1996) while the opposite is indicated for cisplatinum and
paclitaxel (Hawkins et al, 1996).
The hypothesis of an individual genetic predisposition is tested
by Poikonen et al (1994). In patients with primary, node-positive
breast cancer and who were given CMF as adjuvant chemotherapy,
they conclude that leucocyte nadir is associated with favourable
distant disease-free interval and that it could be useful as a bio-
logical marker of chemotherapy efficacy. This is a follow-up and
confirmation of similar work from the same group (Saarto et al,
1997). In this previous paper, based on results from 211 stage II
and III breast cancer patients, it was concluded that a low
leucocyte nadir after another, anthracycline-containing adjuvant
regimen predicated both prolonged distant disease-free interval
and overall survival. The interesting concept of a higher biological
dose intensity connected with low leucocyte nadirs and good prog-
nosis compared to high dose intensity due to lower sensitivity
(higher leucocyte nadir) is discussed.
Pointing in the same direction are studies on the effect on
outcome of dose reductions. In a well conducted, although retro-
spective, study Colleoni et al (1997) found that patients who had
major dose reductions based on severe neutropenia experienced
less benefit from the treatment.
If the results in the papers presented by the Finnish group
(Saarto et al, 1997; Poikonen et al, 1999) are supported by further
documentation, it would support the concept of tailored, individual
dosing based on individual sensitivity, best characterized by the
leucocyte nadir after the first challenges with chemotherapy. An
unresponsive bone marrow after initial standard dose indicates that
the treatment is not well tolerated, but too well tolerated. This
hypothesis should be tested in a prospective, randomized trial
where the patients in the control arm of the trial are given
chemotherapy according to traditional conventions, while the
patients in the experiment are given individualized, tailored doses
of chemotherapy according to bone marrow (leucocyte nadir)
response. Perhaps the Finnish investigators will do this?
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